Sickle Cell Disease

New England CEPAC

ICER will assess the comparative clinical effectiveness and value of crizanlizumab (Novartis) and voxelotor (Global Blood Therapeutics) for the treatment of sickle cell disease. Crizanlizumab, a P-selectin inhibitor, is currently under FDA priority review with an anticipated decision expected in the first half of 2020. Global Blood Therapeutics is planning to initiate and complete a rolling NDA for voxelotor, an HbS polymerization inhibitor, before the end of 2019.

For questions, please contact Catherine Koola, Program Manager, at ckoola@icer-review.org.

Associated Meetings

March 26, 2020 10am-4pm ET

TBA

The New England CEPAC will convene to deliberate and vote on evidence presented in ICER's report on treatments for sickle cell disease.


Key Dates

Associated Materials

08/30/2019

08/30/2019 – 09/20/2019
Public Comments

08/30/2019

09/30/2019
Revised Scoping Document

11/05/2019
Research Protocol

11/26/2019
Model Analysis Plan

01/22/2020
Draft Evidence Report

01/22/2020
Draft Voting Questions

01/22/2020 – 02/19/2020
Public Comment

03/12/2020
Revised Voting Questions

03/12/2020
Evidence Report

03/12/2020
Response to Comments

03/26/2020
Meeting Agenda

03/26/2020
Evidence Presentation

04/16/2020
Final Evidence Report and Meeting Summary

04/16/2020
Report-at-a-Glance